Moderna: positive results for RSV vaccine candidate
The peer-reviewed article summarizes safety and efficacy data from ConquerRSV, the company's Phase 2-3 trial evaluating mRNA-1345.
An accompanying article in the New England Journal of Medicine calls these results 'an important achievement in the realization of effective RSV vaccines, as well as a milestone in the advancement of mRNA vaccines and drugs'.
Moderna claims to be the only company to have developed an mRNA-based RSV vaccine.
The company has submitted applications for mRNA-1345 to regulators worldwide, and is actively preparing for the commercial launch of mRNA-1345 in 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction